Relmada Therapeutics, Inc. Share Price
RLMDRelmada Therapeutics, Inc. Stock Performance
Open $4.13 | Prev. Close $4.00 | Circuit Range N/A |
Day Range $3.92 - $4.14 | Year Range $0.24 - $5.10 | Volume 23,273 |
Average Traded $4.00 |
Relmada Therapeutics, Inc. Share Price Chart
About Relmada Therapeutics, Inc.
Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor, and other diseases related to excessive GABAergic activity. It also develops REL-P11, a modified-release formulation of psilocybin that has completed Phase 1 safety study for the treatment of metabolic disease. Relmada Therapeutics, Inc. was founded in 2004 and is headquartered in Coral Gables, Florida.
Relmada Therapeutics, Inc. Historical Data
| Day | Open | Close | Change % |
|---|---|---|---|
12-Jan-26 | $4.26 | $4.13 | -3.95% |
09-Jan-26 | $4.33 | $4.30 | -3.04% |
08-Jan-26 | $4.30 | $4.43 | +2.78% |
07-Jan-26 | $4.06 | $4.32 | +6.02% |
06-Jan-26 | $4.11 | $4.07 | -3.44% |
05-Jan-26 | $4.22 | $4.21 | -3.33% |
02-Jan-26 | $4.75 | $4.36 | -9.64% |